exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087743 RNA Name: hsa-miR-130a-5p RNA Type: miRNA Chromosome: chr11 Starnd: + Coordinate: Start Site(bp): 57641212 End Site(bp): 57641233 External Links: hsa-miR-130a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: NA miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0000711 chr16 68155889 68160513 + hsa_circ_0000881 chr19 5653125 5654467 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007780.1 chr17 68413623 68524949 + AC011503.2 chr19 23927788 23929287 + AC078846.1 chr7 129604548 129611630 - AC091564.7 chr11 6610883 6616594 - AC124068.2 chr15 89335053 89336161 + AC144548.1 chr12 110387463 110445548 - AL035458.2 chr20 34234840 34281173 - GAS5 chr1 173858559 173868882 - MALAT1 chr11 65497688 65506516 + MCM3AP-AS1 chr21 46229196 46259390 + NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + SNHG5 chr6 85650491 85678932 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + TYMSOS chr18 630886 658340 - XIST chrX 73820649 73852723 - Z93241.1 chr22 42615244 42615907 + ZNF674-AS1 chrX 46545438 46548841 + ZSCAN16-AS1 chr6 28015122 28137293 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.